A detailed history of Geode Capital Management, LLC transactions in Eagle Pharmaceuticals, Inc. stock. As of the latest transaction made, Geode Capital Management, LLC holds 105,846 shares of EGRX stock, worth $68,799. This represents 0.0% of its overall portfolio holdings.

Number of Shares
105,846
Previous 108,004 2.0%
Holding current value
$68,799
Previous $604,000 35.1%
% of portfolio
0.0%
Previous 0.0%

Shares

30 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

SELL
$3.71 - $6.07 $8,006 - $13,099
-2,158 Reduced 2.0%
105,846 $392,000
Q2 2024

Aug 09, 2024

SELL
$3.34 - $5.6 $412,947 - $692,367
-123,637 Reduced 53.37%
108,004 $604,000
Q1 2024

May 13, 2024

BUY
$4.26 - $6.51 $27,033 - $41,312
6,346 Added 2.82%
231,641 $1.21 Million
Q4 2023

Feb 13, 2024

BUY
$4.63 - $15.21 $25,238 - $82,909
5,451 Added 2.48%
225,295 $1.18 Million
Q3 2023

Nov 13, 2023

BUY
$15.21 - $22.88 $73,768 - $110,968
4,850 Added 2.26%
219,844 $3.47 Million
Q2 2023

Aug 11, 2023

BUY
$17.74 - $31.87 $210,059 - $377,372
11,841 Added 5.83%
214,994 $4.18 Million
Q1 2023

May 15, 2023

BUY
$25.06 - $34.09 $71,370 - $97,088
2,848 Added 1.42%
203,153 $5.76 Million
Q4 2022

Feb 13, 2023

BUY
$24.98 - $39.77 $92,625 - $147,467
3,708 Added 1.89%
200,305 $5.85 Million
Q3 2022

Nov 14, 2022

BUY
$26.42 - $47.12 $178,308 - $318,012
6,749 Added 3.55%
196,597 $5.19 Million
Q2 2022

Aug 12, 2022

SELL
$41.26 - $51.35 $630,205 - $784,319
-15,274 Reduced 7.45%
189,848 $8.43 Million
Q1 2022

May 13, 2022

BUY
$44.58 - $52.6 $32,097 - $37,872
720 Added 0.35%
205,122 $10.2 Million
Q4 2021

Feb 11, 2022

SELL
$45.82 - $56.9 $377,877 - $469,254
-8,247 Reduced 3.88%
204,402 $10.4 Million
Q3 2021

Nov 12, 2021

BUY
$43.79 - $55.78 $490,053 - $624,233
11,191 Added 5.56%
212,649 $11.9 Million
Q2 2021

Aug 13, 2021

BUY
$36.86 - $44.5 $564,363 - $681,339
15,311 Added 8.23%
201,458 $8.62 Million
Q1 2021

May 12, 2021

BUY
$40.32 - $50.97 $1.18 Million - $1.49 Million
29,198 Added 18.6%
186,147 $7.77 Million
Q4 2020

Feb 12, 2021

SELL
$41.72 - $51.34 $122,323 - $150,528
-2,932 Reduced 1.83%
156,949 $7.31 Million
Q3 2020

Nov 13, 2020

SELL
$37.02 - $51.28 $227,895 - $315,679
-6,156 Reduced 3.71%
159,881 $6.79 Million
Q2 2020

Aug 13, 2020

BUY
$43.24 - $55.02 $500,200 - $636,471
11,568 Added 7.49%
166,037 $7.97 Million
Q1 2020

May 14, 2020

SELL
$34.37 - $60.07 $228,491 - $399,345
-6,648 Reduced 4.13%
154,469 $7.11 Million
Q4 2019

Feb 13, 2020

BUY
$54.32 - $64.31 $115,538 - $136,787
2,127 Added 1.34%
161,117 $9.68 Million
Q3 2019

Nov 12, 2019

BUY
$53.25 - $59.98 $117,256 - $132,075
2,202 Added 1.4%
158,990 $8.99 Million
Q2 2019

Aug 14, 2019

BUY
$46.61 - $58.45 $255,376 - $320,247
5,479 Added 3.62%
156,788 $8.73 Million
Q1 2019

May 14, 2019

BUY
$38.66 - $51.82 $744,823 - $998,364
19,266 Added 14.59%
151,309 $7.64 Million
Q4 2018

Feb 13, 2019

BUY
$36.72 - $67.73 $468,106 - $863,422
12,748 Added 10.69%
132,043 $5.32 Million
Q3 2018

Nov 13, 2018

BUY
$66.65 - $83.86 $1.15 Million - $1.45 Million
17,260 Added 16.92%
119,295 $8.27 Million
Q2 2018

Aug 14, 2018

BUY
$51.25 - $76.62 $1.16 Million - $1.73 Million
22,621 Added 28.48%
102,035 $7.72 Million
Q1 2018

May 15, 2018

BUY
$52.16 - $66.86 $93,575 - $119,946
1,794 Added 2.31%
79,414 $4.18 Million
Q4 2017

Feb 13, 2018

SELL
$49.6 - $60.87 $787,449 - $966,372
-15,876 Reduced 16.98%
77,620 $4.15 Million
Q3 2017

Nov 14, 2017

BUY
$46.62 - $60.36 $174,405 - $225,806
3,741 Added 4.17%
93,496 $5.58 Million
Q2 2017

Aug 14, 2017

BUY
N/A
89,755
89,755 $7.08 Million

Others Institutions Holding EGRX

About EAGLE PHARMACEUTICALS, INC.


  • Ticker EGRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 13,015,900
  • Market Cap $8.46M
  • Description
  • Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and in...
More about EGRX
Track This Portfolio

Track Geode Capital Management, LLC Portfolio

Follow Geode Capital Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Geode Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Geode Capital Management, LLC with notifications on news.